Karlsruhe

• Silexan® in mild to moderate major depressive disorder Recruiting
  2025-521744-37-00 5 2025-11-17 Mild to moderate major depressive disorder
• A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting
  2024-519654-37-00 10 2025-11-07 Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i … Recruiting
  2024-518365-10-00 5 2025-10-28 Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
• – IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Profici … Recruiting
  2024-519929-38-00 4 2025-10-27 Metastatic Colorectal Cancer without liver metastases
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
  2023-509861-19-01 4 2025-09-30 Diffuse large B-cell lymphoma (DLBCL)
• A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig … Recruiting
  2025-520519-14-00 5 2025-09-03 Atherosclerotic Cardiovascular Disease
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu … Recruiting
  2023-506460-14-00 5 2025-05-07 Chronic kidney disease (CKD) and hypertension.
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro … Recruiting
  2023-508005-24-00 5 2024-08-01 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line tr … Recruiting
  2024-512320-11-00 5 2023-08-09 Primary diffuse large B-cell lymphoma of the central nervous system (P
• A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting
  2024-517966-40-00 4 2023-07-13 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
• Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w … Recruiting
  2022-501808-96-00 4 2023-05-15 Mantle Cell Lymphoma
• A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi … Recruiting
  2022-501187-18-00 5 2023-04-24 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS)
• CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE … Recruiting
  2022-500764-35-00 6 2022-10-13 Patients with advanced HER2-negative, hormone receptor positive (HER2n
• Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or … Recruiting
  2023-507461-26-00 5 2022-09-22 Newly diagnosed acute myeloid leukemia (AML)
• A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di … Recruiting
  2023-507518-28-00 5 2022-09-13 Acute myeloid leukemia
• International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma Recruiting
  2022-501180-40-00 5 2022-06-17 Ewing Sarcoma
• SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years. Recruiting
  2024-510578-25-00 5 2021-11-05 Histologically proven high-risk medulloblastoma, with any of the curre
• HIPEC/FLOT9 - PREVENT Recruiting
  2024-517300-10-01 5 2020-12-17 Resectable diffuse type gastric and gastroesophageal junction Typ II/I
• Controlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irr … Recruiting
  2024-514383-61-00 6 2020-07-07 Diarrhoea predominant irritable bowel syndrome

Showing 25–48 of 111 trials